HRP20190405T1 - Postupci za smanjenje brzine pogoršanja astme korištenjem benralizumaba - Google Patents

Postupci za smanjenje brzine pogoršanja astme korištenjem benralizumaba

Info

Publication number
HRP20190405T1
HRP20190405T1 HRP20190405TT HRP20190405T HRP20190405T1 HR P20190405 T1 HRP20190405 T1 HR P20190405T1 HR P20190405T T HRP20190405T T HR P20190405TT HR P20190405 T HRP20190405 T HR P20190405T HR P20190405 T1 HRP20190405 T1 HR P20190405T1
Authority
HR
Croatia
Prior art keywords
astma
benralizumab
procedures
reducing
duration rate
Prior art date
Application number
HRP20190405TT
Other languages
English (en)
Croatian (hr)
Inventor
Christine Ward
Lorin Roskos
Bing Wang
Donald Raible
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20190405T1 publication Critical patent/HRP20190405T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Bathtubs, Showers, And Their Attachments (AREA)
HRP20190405TT 2013-08-12 2014-08-07 Postupci za smanjenje brzine pogoršanja astme korištenjem benralizumaba HRP20190405T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361864944P 2013-08-12 2013-08-12
EP14835826.0A EP3033101B1 (en) 2013-08-12 2014-08-07 Methods for reducing exacerbation rates of asthma using benralizumab
PCT/US2014/050080 WO2015023504A1 (en) 2013-08-12 2014-08-07 Methods for reducing exacerbation rates of asthma using benralizumab

Publications (1)

Publication Number Publication Date
HRP20190405T1 true HRP20190405T1 (hr) 2019-04-19

Family

ID=52448837

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190405TT HRP20190405T1 (hr) 2013-08-12 2014-08-07 Postupci za smanjenje brzine pogoršanja astme korištenjem benralizumaba

Country Status (26)

Country Link
US (2) US9441037B2 (enExample)
EP (1) EP3033101B1 (enExample)
JP (4) JP6746495B2 (enExample)
KR (2) KR20220057637A (enExample)
CN (2) CN111588848A (enExample)
AU (2) AU2014306956B2 (enExample)
BR (1) BR112016002401A8 (enExample)
CA (1) CA2918105C (enExample)
CY (1) CY1122132T1 (enExample)
DK (1) DK3033101T3 (enExample)
ES (1) ES2716906T3 (enExample)
HK (2) HK1221644A1 (enExample)
HR (1) HRP20190405T1 (enExample)
HU (1) HUE042607T2 (enExample)
LT (1) LT3033101T (enExample)
ME (1) ME03348B (enExample)
MX (1) MX368508B (enExample)
PL (1) PL3033101T3 (enExample)
PT (1) PT3033101T (enExample)
RS (1) RS58404B1 (enExample)
RU (1) RU2676333C2 (enExample)
SG (2) SG11201600481UA (enExample)
SI (1) SI3033101T1 (enExample)
SM (1) SMT201900163T1 (enExample)
TR (1) TR201903312T4 (enExample)
WO (1) WO2015023504A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX368474B (es) * 2013-08-12 2019-10-04 Astrazeneca Ab Uso de benralizumab para mejorar síntomas de asma.
HUE053627T2 (hu) * 2013-08-12 2021-07-28 Astrazeneca Ab Módszerek a kényszerített kilégzési térfogat növelésére asztmásoknál benralizumab használatával
EP3057609A4 (en) * 2013-10-15 2017-03-22 Medlmmune, LLC Methods for treating chronic obstructive pulmonary disease using benralizumab
HRP20211371T1 (hr) * 2013-10-24 2021-11-26 Astrazeneca Ab Stabilne, vodene formulacije protutijela
AU2015204674B2 (en) 2014-01-10 2020-09-03 Anaptysbio, Inc. Antibodies directed against interleukin-33 (IL-33)
US10699274B2 (en) 2015-08-24 2020-06-30 Samsung Electronics Co., Ltd. Apparatus and method for secure electronic payment
US10846696B2 (en) 2015-08-24 2020-11-24 Samsung Electronics Co., Ltd. Apparatus and method for trusted execution environment based secure payment transactions
CA3002761A1 (en) 2015-11-04 2017-05-11 Astrazeneca Ab Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
US11542316B2 (en) 2017-01-04 2023-01-03 Worg Pharmaceuticals (Zhejiang) Co., Ltd. S-Arrestin peptides and therapeutic uses thereof
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
TW202021983A (zh) * 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0811691B1 (en) 1995-09-11 2004-12-01 Kyowa Hakko Kogyo Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
EP1266663A4 (en) 2000-02-15 2003-07-23 Kyowa Hakko Kogyo Kk INDUCER OF EOSINOPHILIC SPECIFIC APOPTOSIS
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2005035583A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Il-5受容体に特異的に結合する抗体組成物
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
DK2068927T3 (da) 2007-05-14 2016-01-18 Medimmune Llc Fremgangsmåder til reducering af eosinofilniveauer
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
MX2012005661A (es) * 2009-11-18 2012-09-07 Medicinova Inc Tratamiento de exacerbacion aguda de asma y reduccion de probabilidad de hospitalizacion de pacientes que sufren de la misma.
RU2737245C2 (ru) * 2010-12-16 2020-11-26 Дженентек, Инк. Способы диагностики и лечения, связанные с ингибированием тн2
US8961965B2 (en) 2011-05-18 2015-02-24 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
KR20140097217A (ko) 2011-11-01 2014-08-06 메디뮨 엘엘씨 급성 천식 악화의 빈도 및 중증도를 감소시키는 방법
HUE053627T2 (hu) * 2013-08-12 2021-07-28 Astrazeneca Ab Módszerek a kényszerített kilégzési térfogat növelésére asztmásoknál benralizumab használatával
MX368474B (es) * 2013-08-12 2019-10-04 Astrazeneca Ab Uso de benralizumab para mejorar síntomas de asma.

Also Published As

Publication number Publication date
US9441037B2 (en) 2016-09-13
AU2014306956A1 (en) 2016-02-04
ES2716906T3 (es) 2019-06-17
EP3033101A4 (en) 2017-07-12
ME03348B (me) 2019-10-20
PT3033101T (pt) 2019-04-02
RU2016108723A3 (enExample) 2018-06-18
MX2016001383A (es) 2016-08-03
JP6746495B2 (ja) 2020-08-26
SMT201900163T1 (it) 2019-05-10
KR20220057637A (ko) 2022-05-09
RU2016108723A (ru) 2017-09-19
BR112016002401A2 (pt) 2017-09-12
CY1122132T1 (el) 2020-11-25
JP2024129139A (ja) 2024-09-26
WO2015023504A8 (en) 2015-09-24
AU2020201327A1 (en) 2020-03-12
HK1225302B (en) 2017-09-08
US20150044202A1 (en) 2015-02-12
WO2015023504A1 (en) 2015-02-19
SI3033101T1 (sl) 2019-04-30
JP2016527324A (ja) 2016-09-08
CN105451760A (zh) 2016-03-30
CN111588848A (zh) 2020-08-28
RS58404B1 (sr) 2019-04-30
DK3033101T3 (en) 2019-04-08
EP3033101B1 (en) 2018-12-19
RU2676333C2 (ru) 2018-12-28
CA2918105A1 (en) 2015-02-19
SG10202005560UA (en) 2020-07-29
MX368508B (es) 2019-10-07
KR20160042121A (ko) 2016-04-18
CA2918105C (en) 2023-02-28
JP2022120009A (ja) 2022-08-17
BR112016002401A8 (pt) 2018-06-12
EP3033101A1 (en) 2016-06-22
HK1221644A1 (zh) 2017-06-09
JP2020128375A (ja) 2020-08-27
SG11201600481UA (en) 2016-02-26
AU2014306956B2 (en) 2019-11-21
US20170198049A1 (en) 2017-07-13
TR201903312T4 (tr) 2019-04-22
PL3033101T3 (pl) 2019-06-28
LT3033101T (lt) 2019-03-25
KR102390714B1 (ko) 2022-04-26
HUE042607T2 (hu) 2019-07-29

Similar Documents

Publication Publication Date Title
HRP20190405T1 (hr) Postupci za smanjenje brzine pogoršanja astme korištenjem benralizumaba
LT3057586T (lt) Bromodomeno inhibitoriai
IL242453B (en) Bipyrazole derivatives as jak inhibitors
EP2969007A4 (en) HISTONE DEMETHYLASE INHIBITORS
AR095266A1 (es) Inhibidores de bromodominios tetraciclicos
IL241321A0 (en) ido inhibitors
IL265496A (en) bace1 inhibitors
ZA201506156B (en) Novel inhibitors
SG11201507958TA (en) Novel viral replication inhibitors
EP3632467C0 (en) COMPLEMENT FACTOR H INHIBITORS
LT3563837T (lt) Terapija bakteriofagu
IL240763B (en) The halopyrazoles as thrombin inhibitors
EP3031897A4 (en) Culture vessel
SMT201800593T1 (it) Inibitore per disturbi retinocoroidei
TH1301003915B (th) การทำให้ตัวยับยั้งเอนไซม์แอลฟ่า1-โปรตีเอสที่ได้จากเซลล์เพาะเลี้ยงบริสุทธิ์
UA27547S (uk) Комплект етикеток для вермуту
GB201307546D0 (en) Laser treatment
ES1078546Y (es) Cinturon - pareo ajustable